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Abstract
Background: The development of heart failure following myocardial infarction (MI) in
patients with diabetes mellitus (DM) is related to the extent of the infarction zone and underly-
ing primary diabetic cardiomyopathy. Echocardiography allows the monitoring of systolic
dysfunction following MI. Left ventricular ejection fraction (LVEF) is one of the most impor-
tant prognostic indicators in patients after MI.
Methods: The aim of the study was to assess the effect of type 2 DM on postinfarct left
ventricular (LV) remodeling in patients with acute ST segment elevation MI treated with
primary percutaneous transluminal coronary angioplasty. One hundred and ten patients were
enrolled to the study and divided into two groups: group 1 included 41 subjects with type 2 DM,
and group 2 included 57 subjects without DM. Echocardiographic parameters of LV systolic
function including LVEF, LV end-diastolic volume (LVEDV), and LV end-systolic volume
(LVESV) were compared between the study groups.
Results: Both study groups showed statistically significant decrease in LVEF. However,
significant LV dilatation was seen only in patients without DM but not in patients with DM.
Conclusion: Long-term DM leads to the remodeling and the fibrosis of cardiac interstitial
tissue, limiting acute ventricular dilatation and resulting in stiffening of the heart. (Folia
Cardiol. 2006; 13: 414–418)
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Introduction
Ischemic heart disease is one of the major pro-
blems in current cardiology practice. The most dan-
gerous form of ischemic heart disease is an acute
myocardial infarction (MI), resulting from the acu-
te occlusion of a coronary artery by a thrombus
developing on an atherosclerotic plaque. Acute co-
ronary occlusion for just 30 minutes may result in
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myocardial necrosis with all its biochemical, histo-
logical, and functional sequelae. The extent of my-
ocardial necrosis and resulting left ventricular (LV)
systolic dysfunction is the major factor affecting
both early and late prognosis following MI. The
extent of myocardial necrosis is related to many
factors including the coronary artery involved, the
extent of myocardium supplied by the involved ar-
tery and the level of occlusion [1]. In addition, the
heart may be “protected” against ischemia, e.g. by the
presence of collateral vessels or preconditioning [2].
Remodeling following MI is a dynamic process le-
ading to multiple changes in myocardium at the
molecular and cellular level and also in the inter-
stitial space. Remodeling is affected by the paten-
cy of the infarct-related artery, the degree of he-
modynamic load, myocardial cell viability in the in-
farct area and neurohormonal activation [3]. Factors
contributing to the adverse remodeling inlude an-
terior wall localization of MI, significant early MI
expansion, persistent occlusion of the infarct-rela-
ted artery, renin-angiotensin system activation, and
diabetes mellitus (DM) [3, 4]. In particular, DM is
associated with the accumulation of numerous ad-
ditional cardiovascular risk factors and also contri-
butes to the adverse remodeling following MI.
Long-lasting DM leads to significantly increased
ventricular wall stiffness, often with increased my-
ocardial thickness [4, 5].
Primary diabetic cardiomyopathy is defined as
abnormal LV myocardial function in diabetic pa-
tients with no coronary atherosclerosis, hyperten-
sion, and clinical symptoms of ischemic heart dise-
ase, eventually leading to heart failure [2, 5].
According to this definition, diabetic cardiomyopa-
thy does not result from the effects of coronary
atherosclerosis, hypertension or cardiac degenera-
tive changes related to aging. Thus, MI superim-
posed on primary diabetic cardiomyopathy should
lead to somewhat different remodeling following MI
compared to patients without DM. Ventricular re-
modeling following MI involves an early and a late
phase. The early phase is associated with increased
end-diastolic pressure and increased wall tension
due to impaired systolic function. This leads to
stretching, thinning, and the separation of cardio-
myocytes that is collectively termed infarct expan-
sion [5, 6]. Chronic increase in end-diastolic cardiac
load activates compensatory hemodynamic and neu-
rohormonal mechanisms, leading to cardiomyocy-
te hypertrophy and interstitial fibrosis. The abnor-
mal function of hypertrophied cardiomyocytes,
manifested by their delayed contraction and rela-
xation, results in further increase in end-diastolic
volume and pressure, thus additionally contributing
to LV dilatation. This is the so-called late phase of
ventricular remodeling [7, 8].
Primary percutaneous transluminal coronary
angioplasty (PTCA) is a superior therapeutic stra-
tegy in acute MI [9, 10], with significant benefits
seen both during the early and long-term follow-up.
The echocardiographic assessment of LV func-
tion allows the monitoring of systolic dysfunction
following MI. Left ventricular ejection fraction
(LVEF) is a major indicator of cardiac function and
prognosis following MI.
Events triggering and accompanying ventricu-
lar remodeling following MI in patients with DM are
similar to those in patients without DM. However,
underlying primary diabetic cardiomyopathy may be
expected to affect the process of remodeling. The
aim of this study was to assess the effect of type 2 DM
on remodeling following ST segment elevation
myocardial infarction (STEMI) in patients treated
with primary PTCA.
Methods
The study group consisted of 110 patients
(72 men, 38 women) aged 43 to 70 years (mean age
59.4 ± 5.4 years) undergoing primary PTCA in
STEMI. Patients with normal LV systolic function
prior to MI, defined as LVEF > 50% as assessed
using the Simpson method, were included. The
patients in our study remained under the care of our
center prior to the occurrence of MI and had an
echocardiogram performed on an outpatient basis
within 6 months before MI.
The patients were divided into two groups.
Group I included 41 patients with type 2 DM and
group II included 57 patients without DM. The du-
ration of type 2 DM was ≥ 5 years. Characteristics
of the study groups is shown in Table 1.
Table 1. Patient characteristics in the study
groups.
Group I Group II P
Men 41 (65.09%) 31 (65.96%) NS
Women 22 (34.92%) 16 (37.21%) NS
Age (years) 57.2±9.8 60.1±7.5 NS
LVEF prior to MI 56.3±4.75 57.04±5.4 NS
HbA1c 6.45±0.91 5.1±0.73 < 0.05
Peak troponin 39.7±3.6 34.9±4.3 NS
I level
Anterior wall MI 30 (47.62%) 21 (44.68%) NS
MI — myocardial infarction; LVEF — left venricular ejection fraction
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The echocardiographic assessment of cardiac
function was performed in day 1 and subsequently
in 3 months following MI. Evaluated parameters in-
cluded LVEF, LV end-diastolic volume (LVEDV)
and LV end-systolic volume (LVESV). Biplane
Simpson method was used. The echocardiographic
studies were performed using the Acuson Sequoia
C 512 system. Only patients with the total occlu-
sion (TIMI 0 flow) of a single major coronary arte-
ry (i.e. 1-vessel disease) before the invasive treat-
ment and TIMI 3 flow in the infarct-related artery
following the invasive treatment were included.
Patients were selected based on the degree of my-
ocardial damage as assessed by peak troponin I level.
Patients with peak troponin I level of 30–50 mg/L
were included in the study.
We evaluated changes in LV systolic function
parameters (LVEF, LVEDV, LVESV) at 3 months
following MI compared to day 1. Both within-group
and between-group comparisons were performed.
Results are expressed as arithmetical means ±
± standard deviation (SD). The distribution of con-
tinuous variables was evaluated using Shapiro-Wilk
test. The statistical significance of the differences
was evaluated using Student t test for parametric
data and Mann-Whitney test for nonparametric data.
P<0.05 was considered statistically significant.
Results
The study groups were compared with regard
to age, gender, LVEF before MI, HbA1c level, tro-
ponin level and the percentage of patients with an-
terior wall MI. Significant difference between the
study groups was seen only in HbA1c level with ele-
vated HbA1c values in patients with type 2 DM in
group I. The results are shown in Table 1.
Significant decrease in LVEF and increase in
LVESV at 3 months following MI was seen in the
patients with DM (Fig. 1, 2). No change of LVEDV
was seen in this group. In the patients without DM,
significant decrease in LVEF and increase in both
LVESV and LVEDV were seen at 3 months follo-
wing MI (Fig. 3–5).
The comparison of evaluated echocardiogra-
phic parameters between the study groups at
3 months revealed significantly higher LVEDV in
patients without DM compared to the patients with
DM (Fig. 6). No significant difference in LVEF and
LVESV between the study groups was seen at
3 months. The results are shown in Table 2.
We also compared relative changes in the eva-
luated echocardiographic parameters in the study
groups between baseline and 3 months following MI.
60 70 80 90 100 110
1 day
3 months
min – [ ± SD] – max×
Figure 3. Comparison of left ventricular end-systolic
volume in Group I.
34 44 54 64
1 day
3 months
min – [ ± SD] – max×
Figure 2. Comparison of left ventricular ejection fraction
in Group II.
20 30 40 50 60
1 day
3 months
min – [ ± SD] – max×
Figure 1. Comparison of left ventricular ejection fraction
in Group I.
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Discussion
Impaired LV systolic function and post-infarction
cardiomyopathy are adverse late sequelae of MI.
Patients with DM may develop diabetic cardiomyopa-
thy and heart failure independently from MI [11, 12].
This results from premature atherogenesis, inclu-
ding the development of both micro- and macroan-
giopathy. In addition, patients with DM are more
commonly affected with hypertension, obesity
and cardiac autonomic neuropathy. Biochemical
60 70 80 90 100 110
1 day
3 months
min – [ ± SD] – max×
130 150 170 190 210
1 day
3 months
min – [ ± SD] – max×
Figure 4. Comparison of left ventricular end-systolic
volume in Group II.
Figure 5. Comparison of left ventricular end-diastolic
volume in Group II.





min – [ ± SD] – max×
Figure 6. Comparison of left ventricular end-diastolic
volume between the study groups at 3 months.
Table 2. Echocardiographic parameters of left ventricular systolic function in patients with diabetes
mellitus (Group I) compared to patients without diabetes mellitus (Group II)
Group I Group II Group I vs. Group II
Day 1 3 months Day 1 3 months 3 months
LVEF 49.2±5.35 41.1±6.69* 51.1±7.9 43.7±5.82* NS
LVEDV 151.0±8.1 155.4±6.8 144.4±7.11 172.2±11.8* Significant
LVESV 77.2±5.82 98.5±6.91* 81.1±6.63 101.1±6.3* NS
LVEF — left ventricular ejection fraction; LVEDV — left ventricular end-diastolic volume; LVESV — left ventricular end-systolic volume; *p < 0.05
Table 3. Comparison of relative changes in eval-
uated echocardiographic parameters (difference
between values at 3 months and baseline values)
in patients with diabetes mellitus (Group I) and
patients without diabetes mellitus (Group II)




DLVEF — change in left ventricular ejection fraction; DLVEDV — change
in left ventricular end-diastolic volume; DLVESV — change in left
ventricular end-systolic volume; *p < 0.05
A statistically significant difference was seen only
for the change in LVEDV, with higher increase in
LVEDV in patients without DM compared to the
patients with DM. No significant difference in the
change in LVEF and LVESV between the study gro-
ups was seen. The results are shown in Table 3.
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abnormalities include nonenzymatic protein and li-
pid glycation, increased ATP synthesis from free
fatty acids and the increased levels of toxic products
of these processes. At the same time, fibroblast pro-
liferation and collagen production are increased, le-
ading to increased fibrosis [7, 11]. All these mecha-
nisms impair LV diastolic function, manifested by
increased isovolumic relaxation time, increased
E wave deceleration time, and the reversal of the
E/A ratio [13]. In summary, mechanisms leading to
LV diastolic dysfunction are related to dysfunction
and morphological changes in both cardiomyocytes
and the extracellular matrix. In particular, abnor-
mal calcium homeostasis and energy balance is seen
in cardiomyocytes, as manifested by abnormal ADP/ATP
ratio and the major pathogenic factor in the extra-
cellular matrix is the change in fibrillar collagen.
These processes lead to increased cardiac stiffness.
Changes in cardiac wall stiffness may be assessed
by measuring the pressure-volume relationship
during the diastole [8]. Increasing cardiac wall stif-
fness leads to the increased end-diastolic pressure
regardless of end-diastolic volume and progressi-
vely decreasing LVEF, i.e. the impairment of sy-
stolic function. The increase in ratio of end-diasto-
lic pressure to LVEF is a measure of increasing LV
wall stiffness. Long-lasting DM leads to significan-
tly increased wall stiffness, often with increased
myocardial thickness [8, 11, 12]. Infarction occur-
ring in structurally and functionally abnormal my-
ocardium in a patient with DM may be expected to
result in a variant of ventricular remodeling [14] and
the present study attempted to evaluate such diffe-
rences. The evaluation of selected echocardiographic
parameters of LV systolic function showed that a de-
crease in LVEF in patients with type 2 DM is not as-
sociated with significant LV dilatation. Increased car-
diac wall stiffness in DM counteracts this ventricular
remodeling, at least in the early phase following MI.
A major factor affecting cardiac function impairment
in patients with DM was an increase in LVESV. In
contrast, decrease in LVEF with significant LV dila-
tation and increase in LVESV were seen in patients
without DM. Similar changes in hemodynamic para-
meters in patients with DM developing heart failure
were reported by Giles [13]. Future studies will esta-
blish whether changes in hemodynamic parameters
seen at 3 months following MI in patients with DM
are maintained during a longer-term follow-up.
In the present study, decrease in LVEF was
found in both study groups but ventricular remode-
ling in patients without DM resulted in significant
LV dilatation that was not seen in patients with DM.
Long-term DM leads to the remodeling and fibrosis
of cardiac interstitial tissue, limiting acute ventricu-
lar dilatation and resulting in stiffening of the heart.
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